missing translation for 'onlineSavingsMsg'
Learn More

R&D Systems™ Recombinant Human Prostatic Acid Phosphatase/ACPP

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.

Brand:  R&D Systems™ 6240-AP-010

Product Code. 18319487

  • 347.00€ / 10µg

Please to purchase this item. Need a web account? Register with us today!

Explore more special offers
This item is not returnable. View return policy

Description

Description

Measured by its ability to cleave a substrate, p-Nitrophenyl phosphate (pNPP). The specific activity is >100,000 pmol/min/ug, as measured under the described conditions.
Specifications

Specifications

P15309
Supplied as a 0.2 μm filtered solution in Tris and NaCl.
M.W. (Observed): 43-55 kDa, reducing conditions; M.W. (theoretical): 41 kDa
10 μg
Do not freeze. 3 months from date of receipt, 2°C to 8°C as supplied. 1 month, 2°C to 8°C under sterile conditions after opening.
ACPP
Recombinant
Prostatic Acid Phosphatase/ACPP
Enzyme Activity
55
Prostatic Acid Phosphatase/ACPP
Mouse myeloma cell line, NS0-derived human Prostatic Acid Phosphatase/ACPP protein Met1-Gln379, with a C-terminal 6-His tag
<1.0 EU / 1 μg of the protein by the LAL method.
Unconjugated
>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie™ Blue stain (at 5 μg / lane)
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.